$95.05
+4.82 (+5.34%)
BGSI News30 articles
Bitmine Stock Slides 7% as Ether Decline Pressures $10.7B Crypto Holdings
Bitmine stock dropped 7.3% as ether slid 5.1%, threatening the value of its massive $10.7B crypto treasury. The company warned of risks to asset values and capital-raising ability.
Gold Dips Below $4,000 as Dollar Strengthens and Fed Hawkishness Weighs
Gold slipped under $4,000 an ounce for the first time in seven months as the dollar strengthened and traders increased bets on further Fed rate hikes, sparking a broad precious metals selloff.
Hershey's $1.7B Rally on Cocoa Margin Hopes Faces Weather Risk
Hershey shares surged 4.9% to $179.27, adding $1.7 billion in value, as investors bet on margin recovery from lower cocoa costs. However, rising cocoa prices due to Ivory Coast weather risks threaten the rebound.
Iovance Biotherapeutics Stock Surges on $89.7 Million ATM Offering
Iovance shares rose 9.4% after launching an $89.65 million ATM stock sale, as investors balance dilution risks against the potential for accelerated Amtagvi revenue growth.
Viking Therapeutics Surges on Obesity Drug Hopes
Viking Therapeutics shares climbed 6% to $34.30 as investors bet on upcoming Phase 3 data for its obesity drug VK2735, expected in Q3 2026.
Catheter Precision Surges 34.5% Premarket on Patent News and Resale Filing
Catheter Precision (VTAK) surged 34.5% premarket following a flurry of announcements including new patents, a sports partnership, and a resale share filing for 68.1 million shares.
Nexentis Shares Surge 156% on AI Drug Discovery Pact, Then Retreat
Nexentis shares skyrocketed 156% after announcing an AI drug discovery deal and a $2.9 million stock-and-warrant offering, but declined 26% in after-hours trading amid dilution concerns.
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
Apogee Therapeutics stock jumped 47% after AbbVie agreed to buy the company for $135.11 per share in cash, adding late-stage eczema drug zumilokibart.
PG&E Outages Hit 9,000 Across Three Counties Amid Fire Weather
PG&E outages affected over 9,000 customers in Monterey, Clovis, and Shasta County amid storms and fire weather, underscoring utility challenges in maintaining reliability during peak summer demand.
Wolfspeed Surges 18% Then Files Share Resale, Testing AI Chip Rally
Wolfspeed shares surged 18% before filing to register 24 million shares for resale, raising dilution concerns. The silicon carbide chipmaker's AI-driven rally faces a test when markets reopen.
CervoMed Shares Surge on Patent News, Then Retreat After $10M Stock Offering
CervoMed shares surged to $7.75 after a U.S. patent allowance for neflamapimod in pure DLB, but gave back most gains after announcing a $10 million stock offering at $4 per share. The stock last traded at $4.14, up 8.7%.
UniQure Holds Gains as FDA Signals Path for Huntington's Gene Therapy Filing
UniQure shares jumped 78.4% after the FDA said Phase I/II data could support an accelerated-approval filing for its Huntington's disease gene therapy AMT-130. A BLA is planned for Q3 2026.
The Agency Expands in Central America with New Belize Office in Placencia
The Agency has opened its first Belize office in Placencia, expanding its Central America network. The move aims to capture rising foreign buyer interest, though past fraud cases remain a warning for investors.
FDA Greenlights uniQure's Accelerated Approval Path for Huntington's Gene Therapy
uniQure shares surged 78% premarket after the FDA agreed to accept three-year Phase I/II data as the basis for an accelerated approval filing for AMT-130 in Huntington's disease, reviving the near-term U.S. path for the potential first disease-modifying treatment.
Outlook Therapeutics Surges on FDA Review of Wet AMD Treatment
Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted BLA for ONS-5010/LYTENAVA, setting a PDUFA target date of July 29, 2026.
Bitmine Stock Rises as Ethereum Holdings Hit 5.62 Million ETH
Bitmine Immersion Technologies (BMNR) jumped 6.21% to $17.11 after revealing its Ethereum treasury reached 5,620,754 ETH, representing 4.66% of total supply.
Intellia Therapeutics Surges 23% on Promising Phase 3 Data for CRISPR Therapy
Intellia Therapeutics shares surged 23% to $14.92 after Phase 3 data showed lonvo-z reduced hereditary angioedema attacks by up to 91% versus placebo, with FDA filing as the next catalyst.
AmEx to Acquire TheFork from TripAdvisor for $700M, Expanding Dining Network
American Express will acquire TheFork from TripAdvisor for $700 million in cash, expanding its dining network to 75,000 bookable venues and allowing TripAdvisor to focus on its Experiences segment.
BitMine's Ethereum Holdings Surge to 5.62M ETH, Stock Climbs Ahead of Preferred Debut
BitMine Immersion Technologies shares jumped 6.7% to $17.19 after revealing a massive Ethereum treasury of 5.62 million ETH, ahead of its Series A preferred stock listing on the NYSE.
Ethereum Rebound Watch: BitMine Accumulates 5.62M ETH, Lee's $22K Target in Focus
BitMine boosts Ethereum stash to 5.62M ETH, reigniting debate over Tom Lee's $22,000 target as ETH trades near $1,775.
Cuban Dumps Bitcoin, Calls It 'Lost the Plot' as Price Tops $64K
Mark Cuban says Bitcoin has lost its purpose as a hedge, revealing he sold most of his holdings before recent conflicts, even as BTC briefly topped $64,000.
Bitmine Stock Climbs After Preferred Share Sale, Ethereum Accumulation
Bitmine Immersion Technologies shares gained 5.6% to $16.52 after closing a $273.8M preferred stock sale, with proceeds likely for Ethereum purchases and staking. The firm now holds 5.54M ETH, or 4.59% of total supply.
Theriva Biologics Surges on Phase 1 Cancer Data, But Risks Remain
TOVX surged 74.6% on Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump is not based on approval or revenue.
Outlook Therapeutics Surges on FDA Review Progress for Lytenava
Outlook Therapeutics shares surged 26% to $0.89 as the FDA began a 60-day review of Lytenava after a successful appeal, though the stock faces Nasdaq delisting and dilution risks.
Redwire Stock Tumbles on $500M At-The-Market Offering
Redwire shares plunged 15.19% to $15.75 after unveiling a new $500 million at-the-market stock sale plan, replacing a prior $350 million program, raising dilution concerns.
Epsium Enterprise Rockets 72% in Wild Nasdaq Session Then Plunges
Epsium Enterprise shares skyrocketed 72% on massive volume, then fell 18.5% after hours. The Macau beverage wholesaler's rally comes despite declining revenue and a net loss.
Costco Cuts Kirkland Prices on Select Items, New Florida Store on the Horizon
Costco slashed prices on some Kirkland Signature items by up to $10, aiming to drive membership renewals, while preparing to open a new warehouse in Pensacola, Florida. Q3 results showed strong sales growth.
BitMine Shares Surge as Ether Holdings Near 5% Supply Goal
BitMine shares jumped 6% as its ether stash hit 5.54 million tokens, nearing its 5% supply target. The company also priced a $273.8 million preferred stock offering.
Tango Therapeutics Soars as Pancreatic Cancer Combo Shows 92% Response Rate
Tango Therapeutics shares rose sharply in premarket trading Monday after reporting a 92% objective response rate for its pancreatic cancer drug combo, with plans to move into Phase 3 testing.